Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you consider a PARP inhibitor in a patient who harbors a germline BRCA mutation who has metastatic HER2 negative gastric cancer?
Related Questions
Are you incorporating TTFields into treatment protocols for locally advanced pancreatic cancer based on the PANOVA-3 study?
How does the presence of CNS disease affect your choice of first line therapy in Her2+ gastric adenocarcinoma?
Would you recommend radiation or chemoradiation in a patient with cholangiocarcinoma s/p surgery and adjuvant treatment with single hepatic metastasis 3 years later?
What second-line therapy would you offer a patient with metastatic colon cancer with HER2 IHC 3+ amplification and KRAS G12D mutation whose disease progressed on FOLFOX?
What maintenance therapy do you recommend for metastatic gastric adenocarcinoma with continued response to FOLFOX with zolbetuximab after oxaliplatin removal?
What adjuvant treatment would you give to a locally advanced esophageal adenocarcinoma status post neoadjuvant FLOT s/p resection with positive margins?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
What is your approach for adjuvant chemotherapy for a patient with colon adenocarcinoma, pMMR, T2 with 3 positive lymph nodes and 2 pericolic adipose tumor deposits?
How do you approach patients with partially occlusive thrombus in the splenic vein posterior to the pancreatic cancer lesion?
Would you change treatment approach for rectal cancer with an associated intussusception?
